Soluble PD-L1 as an early marker of progressive disease on nivolumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003527
Abstract: Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma… read more here.
Keywords: treatment; progressive disease; disease; rcc ... See more keywords
Soluble Programmed Cell Death Ligand-1 (sPD-L1) Levels in Various Cancer Types and Normal Populations.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical laboratory"
DOI: 10.7754/clin.lab.2022.220701
Abstract: BACKGROUND To date, PD-L1 expression in tumor tissue, assessed by immunohistochemical stain, is clinically applicable as a predictive companion biomarker for PD-1/PD-L1 inhibitor which has been highlighted over the past several years. Before blood-based sPD-L1… read more here.
Keywords: cancer types; spd; various cancer; spd levels ... See more keywords